RxDoctor Payments Data

Ivan Fundora Gonzalez, MD

General Practice · Miami, FLNPI 1568036010

Payments from drug & device makers

$462in general payments, 2019–2025

Across 27 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$120
  • Lilly USA, LLC$99
  • Novo Nordisk$61
  • Boehringer Ingelheim$61
  • Amgen$54
  • Novartis$22
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$120
Lilly USA, LLC7$99
Novo Nordisk3$61
Boehringer Ingelheim3$61
Amgen3$54
Novartis1$22
Bayer1$16
Pfizer1$15
GSK1$13

How this compares

$462 in reported general payments places this provider in the 60th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$10,558
Medicare patients
20
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide191$200,452
FarxigaDapagliflozin Propanediol252$195,820
JardianceEmpagliflozin204$173,190
EliquisApixaban197$124,771
OzempicSemaglutide106$108,194
VascepaIcosapent Ethyl234$84,719
SynjardyEmpagliflozin/Metformin Hcl76$67,610
XareltoRivaroxaban90$60,105
Soliqua 100-33Insulin Glargine/Lixisenatide64$49,208
EntrestoSacubitril/Valsartan67$45,756
LinzessLinaclotide67$35,210
MounjaroTirzepatide20$21,134
RybelsusSemaglutide17$19,876
JanuviaSitagliptin Phosphate25$15,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$61$254,830302 claims
Lilly USA, LLCTrulicity, Mounjaro$99$221,585211 claims
AstraZenecaFarxiga, Brilinta, Symbicort$120$209,049295 claims
Novo NordiskOzempic, Rybelsus$61$128,071123 claims
PfizerEliquis$15$124,771197 claims
NovartisEntresto$22$45,75667 claims
GSKTrelegy Ellipta, Breo Ellipta$13$28,60449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →